Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Patients with cancer, especially those receiving anticancer therapy, are at risk amidst the coronavirus disease 2019 (COVID-19) pandemic. Given the frequency of asymptomatic COVID-19, and presymptomatic transmission, symptom-based screening may inadequately triage patients to safely resume anticancer therapy.We thus implemented a pilot microbiologic screening program in Al Zahra Hospital in the United Arab Emirates (UAE), identifying presymptomatic COVID-19 in nearly 1 in 10 patients with cancer. We have since expanded this program across serial anticancer therapy cycles.
JAMA Oncology , résumé, 2019